Drug Allergy and Hypersensitivity
8.1 Beta-Lactam Allergy and De-labelling
The Problem: The"90% Fake News" Label
If you walk into any hospital ward today, you will see"Penicillin Allergy" written on red wristbands everywhere. It is the most common drug allergy label in the world. However, the data tells a shocking story: fewer than 10% of these patients are truly allergic.
Why does this happen? Usually, a child has a viral rash while taking amoxicillin. The parents assume it is an allergy, the doctor writes it down to be safe, and that label sticks for life.
In 2026, we view this label not just as a nuisance, but as a patient safety risk. Patients with an incorrect penicillin allergy label are:
Given broad-spectrum antibiotics (like Vancomycin or Ciprofloxacin) which are more toxic.
More likely to develop superbugs like C. difficile or MRSA.
Subject to longer hospital stays.
Therefore, de-labelling—the process of removing this incorrect label—is now a core competency (Specialty CiP 1) for all trainees.
Risk Stratification: The"Traffic Light" System
We cannot test everyone in a specialist clinic; there are simply too many patients. The solution is Risk Stratification. This means sorting patients into groups based on their history to decide who needs a specialist and who can be tested safely on the ward.
1. Low Risk (Green Light)
Who are they? Patients who had a rash (not hives) more than 10 years ago, or patients who only experienced side effects like nausea or headache.
The 2026 Approach: These patients do not need skin testing. The skin test is painful, expensive, and can actually give false positives.
Action: We proceed straight to a Direct Oral Challenge (DOC). This means giving the patient a single dose of amoxicillin (usually 250mg or 500mg) and watching them for one hour.
Service Model: In modern hospitals, this is often a"nurse-led" or"pharmacist-led" service. A specialist does not need to be in the room, provided a doctor is nearby.
2. Moderate Risk (Amber Light)
Who are they? Patients with a history of urticaria (hives) or an itchy rash that happened recently (less than 10 years ago).
The Risk: There is a small but real chance they still have IgE antibodies.
Action: These patients require Skin Testing (skin prick and intradermal tests) first. If the skin test is negative, we then proceed to the oral challenge.
3. High Risk (Red Light)
Who are they? Anyone with a history of:
Anaphylaxis: Throat closing, wheezing, collapse.
SCAR (Severe Cutaneous Adverse Reactions): This includes Stevens-Johnson Syndrome (SJS) or DRESS syndrome. These are blistering skin diseases that can be fatal.
Action: Do not challenge. These patients require strict avoidance and specialist evaluation. We never perform oral challenges on patients with a history of blistering skin reactions.
Setting Up a De-labelling Service
As a trainee, you may be asked to design a de-labeling pathway. The"2026 Standard" is the Point-of-Care Model.
In the past, we referred everyone to the allergy clinic. Now, we bring the test to the patient. For example, a pharmacist reviewing a patient's chart on the Orthopedic ward notices a"Penicillin Allergy" label. They take a quick history. If it sounds"Low Risk," they get approval to give the test dose right there on the ward (with consent).
Evidence Base: Recent large-scale studies (2024-2025) have shown that Direct Oral Challenge in low-risk patients is incredibly safe. The rate of severe reaction is near zero. Even if a rash occurs, it is usually mild and easily treated with antihistamines.
8.2 Perioperative and General Anaesthetic Hypersensitivity
The Nightmare Scenario
Imagine this: A patient is on the operating table. The anaesthetist induces sleep. Suddenly, the heart rate shoots up, the blood pressure crashes to unr
